The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: ANA, ANA Screen IFA with Reflex to Titer and Pattern IFA, ANA with Reflux
Also known as: C-Reactive Protein, CReactive Protein CRP, CRP
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Also known as: ACPA, Anti-CCP, Anti-citrulline Antibody, Anti-cyclic Citrullinated Peptide, Anti-Cyclic Citrullinated Peptide (CCP) Antibody IgG, CCP, CCP Antibody, Citrullinated Peptide (CCP) IgG, Cyclic Citrullinated Peptide Antibody, Cyclic Citrullinated Peptide CCP Antibody IgG
Also known as: RF
Also known as: Rheumatoid Factor IgA
Also known as: Rheumatoid Factor IgG
Also known as: ESR, SED RATE, Sed Rate by Modified Westergren ESR
Also known as: Serum Urate, UA
The Rheumatoid Arthritis - Comprehensive panel contains 10 tests with 62 biomarkers.
Brief Description: The Rheumatoid Arthritis - Comprehensive Panel is the most detailed and extensive diagnostic tool available for assessing and monitoring rheumatoid arthritis (RA) and related autoimmune conditions. This panel combines a wide array of tests to evaluate the presence and severity of RA, monitor treatment effectiveness, and check for potential complications or coexisting conditions. It is designed for individuals with confirmed RA, those with symptoms suggestive of RA or other autoimmune diseases, and patients under treatment for RA to provide a complete health overview.
Collection Method: Blood Draw
Specimen Type: Whole Blood and Serum
Test Preparation: Fasting specimen is preferred.
Important: This panel contains ANA Screen IFA with Reflex to Titer and Pattern #249 which is a Reflex test. If ANA Screen, IFA is positive, then ANA Titer and Pattern will be performed at an additional charge of $24.95
The Comprehensive Panel is typically ordered for individuals with a diagnosis of RA to assess disease activity comprehensively and monitor treatment response. It may also be recommended for patients with unclear diagnosis despite previous testing, to differentiate RA from other autoimmune or inflammatory conditions. Additionally, it's useful for evaluating patients with symptoms that overlap with those of RA, such as joint pain and inflammation, fatigue, and morning stiffness.
The panel evaluates a broad spectrum of biomarkers essential for a thorough assessment of rheumatoid arthritis:
ANA Screen, IFA with Reflex to Titer and Pattern: Detects antinuclear antibodies to identify autoimmune activity, which is a hallmark of various autoimmune disorders, including RA.
C-Reactive Protein (CRP): A sensitive marker of inflammation that can indicate active RA or other inflammatory conditions.
Complete Blood Count with Differential and Platelets and Comprehensive Metabolic Panel (CMP): Assess overall health, organ function, and detect side effects of medications used in RA treatment.
Cyclic Citrullinated Peptide (CCP) IgG Antibody: Highly specific for RA, indicating the disease's presence and potential severity.
Rheumatoid Factor, IgA, and IgG: Identify antibodies associated with RA, providing insights into the immune system's role in the disease.
Sed Rate (ESR): Another inflammation marker, often elevated in active RA.
Uric Acid: High levels can indicate gout, which may coexist with or mimic RA.
The Comprehensive Panel aids in diagnosing and managing:
Rheumatoid Arthritis: Through specific markers like anti-CCP antibodies and rheumatoid factor, signaling an autoimmune attack on the joints.
Autoimmune Disorders: ANA testing can indicate systemic autoimmune activity beyond RA.
Inflammation and Infection: Elevated CRP and ESR levels can point to active inflammation, not necessarily limited to RA.
Healthcare professionals utilize the comprehensive results to fine-tune treatment strategies, considering disease severity, treatment efficacy, and the patient's overall health. This panel supports a holistic approach to RA management, encompassing disease-modifying treatments, symptom management, and monitoring for treatment side effects or coexisting conditions.
The Rheumatoid Arthritis - Comprehensive Panel stands as a critical resource for individuals with RA, offering unparalleled insights into the disease's complexities. By providing an extensive overview of relevant biomarkers, this panel enables informed decision-making, personalized treatment plans, and optimized patient care, ensuring a proactive and comprehensive approach to managing rheumatoid arthritis and its systemic effects.
We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.